keyword
MENU ▼
Read by QxMD icon Read
search

pharmacokinetics, antidepressant

keyword
https://www.readbyqxmd.com/read/28303314/-genetic-tests-for-controlling-treatment-with-antidepressants
#1
T Bschor, C Baethge, C Hiemke, B Müller-Oerlinghausen
In clinical practice, there is a need for a more individualized selection of antidepressants and adequate dosage. The investigation of pharmacokinetically relevant genes is a promising approach to assist this selection. In the past 2 years, two commercially available tests have been subject of advertisement, a test from Stada, which analyses variants of the cytochrome P450 isoenzymes CYP2D6 and CYP2C19 and a test from HMNC Brain Health, which analyses variants of the ABCB1 gene. The costs for both kits are not covered by the statutory health insurance and it is therefore proposed that the patients are invoiced directly in the form of individual healthcare payment...
March 16, 2017: Der Nervenarzt
https://www.readbyqxmd.com/read/28288906/an-aop-analysis-of-selective-serotonin-reuptake-inhibitors-ssris-for-fish
#2
REVIEW
M Danielle McDonald
Pharmaceuticals and personal care products (PPCPs) are found in measureable quantities within the aquatic environment. Selective serotonin reuptake inhibitor (SSRI) antidepressants are one class of pharmaceutical compound that has received a lot of attention. Consistent with most PPCPs, the pharmacokinetics and physiological impacts of SSRI treatment have been well-studied in small mammals and humans and this, combined with the evolutionary conservation of the serotonergic system across vertebrates, allows for the read-across of known SSRI effects in mammals to potential SSRI impacts on aquatic organisms...
March 10, 2017: Comparative Biochemistry and Physiology. Toxicology & Pharmacology: CBP
https://www.readbyqxmd.com/read/28286537/smoking-and-antidepressants-pharmacokinetics-a-systematic-review
#3
REVIEW
Pedro Oliveira, Joana Ribeiro, Helena Donato, Nuno Madeira
BACKGROUND: Despite an increasingly recognized relationship between depression and smoking, little is known about how smoking influences antidepressant response and treatment outcomes. The aim of this study was to systematically review the evidence of the impact of smoking on new-generation antidepressants with an emphasis on the pharmacokinetic perspective. METHODS: We present a systematic review of clinical trials comparing the serum levels of new-generation antidepressants in smokers and nonsmokers...
2017: Annals of General Psychiatry
https://www.readbyqxmd.com/read/28245750/pharmacokinetic-profiles-contribute-to-the-differences-in-behavioral-pharmacology-of-071031b-enantiomers-as-novel-serotonin-and-norepinephrine-reuptake-inhibitors
#4
Rui Xue, Ying Li, Xin-Hua He, Zeng-Liang Jin, Shi-Yong Fan, Ting-Ting Zhang, Nuo-Min Li, Li Yuan, Ai-Ping Zheng, Bo-Hua Zhong, Yun-Feng Li, You-Zhi Zhang
Our previous study indicated that a chiral compound 071031B was a novel serotonin and noradrenaline reuptake inhibitor with superior antidepressant activity compared to duloxetine. The present study aimed to investigate chiral pharmacology differences of 071031B enantiomers, S-071031B and R-071031B, and disclose mechanisms underlying the behavioral differences based on target profiles and pharmacokinetic profiles. In vivo behavioral tests indicated that S-071031B was more potent than R-071031B in two depression models (the forced swimming test in mice and rats) and two pain models (the acetic acid-induced writhing and formalin tests in mice)...
March 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28244813/pharmacogenomics-of-autism-spectrum-disorder
#5
Jacob T Brown, Seenae Eum, Edwin H Cook, Jeffrey R Bishop
Autism spectrum disorder (ASD) is characterized by persistent deficits in social communication and interactions as well as restricted, repetitive behaviors and interests. Pharmacologic interventions are often needed to manage irritability, aggressive behaviors and hyperactivity. Pharmacogenomic studies have investigated genetic associations with treatment response and side effects in an attempt to better understand drug mechanisms in hopes of optimizing the balance of symptom improvement versus side effects...
March 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28236991/-how-to-assess-curative-and-or-preventive-effects-of-psychotropic-drugs
#6
T Bottai, D Pringuey, R Belzeaux, M Adida, J-M Azorin
Proving the efficacy of a psychotropic drug is a medical, scientific and ethical need. Psychotropic drug development is now a highly complex process, which takes several years and which is very expensive. It involves multiple steps of preclinical and clinical pharmacological refinement and testing. Methodology of studies to prove curative or preventive effect of psychotropic drugs is well codified. Preclinical studies include pharmacokinetic data, toxicology and performance in various animal models of pathology...
December 2016: L'Encéphale
https://www.readbyqxmd.com/read/28229443/-desvenlafaxine-and-neuropathic-pain-additional-clinical-benefits-of-a-second-generation-serotonin-noradrenaline-reuptake-inhibitor
#7
REVIEW
A Alcantara-Montero
INTRODUCTION: Desvenlafaxine is the third antidepressant within the group of serotonin-norepinephrine reuptake inhibitors. The latest clinical practice guidelines consulted agree that tricyclic antidepressants, dual (venlafaxine/duloxetine) and gabapentin/pregabalin antiepileptics, are the first-line drugs in the treatment of neuropathic pain, being tramadol, lidocaine 5% patches and capsaicin 8% patches of second-line drugs, while strong opioids constitute a third line treatment. The interaction between the binomial pain and depression is very frequent, being the psychological complication more frequent in patients with chronic pain...
March 1, 2017: Revista de Neurologia
https://www.readbyqxmd.com/read/28228056/brexpiprazole
#8
Marija Markovic, Alyssa Gallipani, Krina H Patel, Megan Maroney
OBJECTIVE: To review the pharmacology and clinical data for brexpiprazole in schizophrenia and major depressive disorder (MDD). DATA SOURCES: An English-language literature search using PubMed and MEDLINE was performed using the term brexpiprazole. All articles containing human clinical trial data published up to September 2016 were evaluated for inclusion as well as information from the manufacturer's product labeling. STUDY SELECTION/DATA EXTRACTION: Phase 3 trials for brexpiprazole were evaluated...
April 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28179816/sex-differences-in-the-psychopharmacological-treatment-of-depression
#9
John J Sramek, Michael F Murphy, Neal R Cutler
Although a number of studies have observed that females respond better to serotonergic antidepressants than males and that postmenopausal females have a diminished response to antidepressants compared with younger females, there are also studies that conflict with both of these findings, making any generalizations regarding sex differences difficult to make. Sex variance in antidepressant efficacy and pharmacokinetics profiles have been attributed to sex-based physiological differences, behavioral differences, related disorders, and sex-specific conditions, including pregnancy and menopause...
December 2016: Dialogues in Clinical Neuroscience
https://www.readbyqxmd.com/read/28178974/antidepressant-prescribing-in-the-precision-medicine-era-a-prescriber-s-primer-on-pharmacogenetic-tools
#10
REVIEW
Chad A Bousman, Malcolm Forbes, Mahesh Jayaram, Harris Eyre, Charles F Reynolds, Michael Berk, Malcolm Hopwood, Chee Ng
About half of people who take antidepressants do not respond and many experience adverse effects. These detrimental outcomes are in part a result of the impact of an individual's genetic profile on pharmacokinetics and pharmcodynamics. If known and made available to clinicians, this could improve decision-making and antidepressant therapy outcomes. This has spurred the development of numerous pharmacogenetic-based decision support tools. In this article, we provide an overview of pharmacogenetic decision support tools, with particular focus on tools relevant to antidepressants...
February 8, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/28079463/influence-of-abcb1-polymorphisms-and-serum-concentrations-on-venlafaxine-response-in-patients-with-major-depressive-disorder
#11
Gul Ozbey, Feryal Cam Celikel, Birgul Elbozan Cumurcu, Derya Kan, Berna Yucel, Ekrem Hasbek, Ferda Percin, Ismail Cüneyt Guzey, Canan Uluoglu
BACKGROUND: The pharmacokinetics and the pharmacodynamics of antidepressants show large inter-individual variations which result in unpredictable clinical responses. AIM: The aim of the study was to examine the effect of ABCB1 polymorphisms and the serum concentrations on the efficacy and tolerability of venlafaxine in patients with major depressive disorder (MDD). METHODS: Fifty-two outpatients who met the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria for MDD were recruited for the study...
April 2017: Nordic Journal of Psychiatry
https://www.readbyqxmd.com/read/28068459/does-pharmacogenomic-testing-improve-clinical-outcomes-for-major-depressive-disorder-a-systematic-review-of-clinical-trials-and-cost-effectiveness-studies
#12
Joshua D Rosenblat, Yena Lee, Roger S McIntyre
OBJECTIVE: Pharmacogenomic testing has become scalable and available to the general public. Pharmacogenomics has shown promise for predicting antidepressant response and tolerability in the treatment of major depressive disorder (MDD). In theory, pharmacogenomics can improve clinical outcomes by guiding antidepressant selection and dosing. The current systematic review examines the extant literature to determine the impact of pharmacogenomic testing on clinical outcomes in MDD and assesses its cost-effectiveness...
January 3, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28013355/effect-of-sildenafil-on-the-activity-of-some-antidepressant-drugs-and-electroconvulsive-shock-treatment-in-the-forced-swim-test-in-mice
#13
Katarzyna Socała, Dorota Nieoczym, Elżbieta Wyska, Piotr Wlaź
Sildenafil, a potent and selective inhibitor of phosphodiesterase type 5, is used clinically to treat erectile dysfunction and pulmonary arterial hypertension. It is often taken by patients suffering from depression and receiving antidepressant drug treatment. However, its influence on the efficacy of antidepressant treatment was not sufficiently studied. Therefore, the aim of the present study was to investigate the influence of sildenafil on the anti-immobility action of several antidepressant drugs (i.e...
December 24, 2016: Naunyn-Schmiedeberg's Archives of Pharmacology
https://www.readbyqxmd.com/read/27941941/potentiation-of-amitriptyline-anti-hyperalgesic-like-action-by-astroglial-connexin-43-inhibition-in-neuropathic-rats
#14
Tiffany Jeanson, Adeline Duchêne, Damien Richard, Sylvie Bourgoin, Christèle Picoli, Pascal Ezan, Franck Mouthon, Christian Giaume, Michel Hamon, Mathieu Charvériat
Antidepressants, prescribed as first line treatment of neuropathic pain, have a limited efficacy and poorly tolerated side effects. Because recent studies pointed out the implication of astroglial connexins (Cx) in both neuropathic pain and antidepressive treatment, we investigated whether their blockade by mefloquine could modulate the action of the tricyclic antidepressant amitriptyline. Using primary cultures, we found that both mefloquine and amitriptyline inhibited Cx43-containing gap junctions, and that the drug combination acted synergically...
December 12, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27900470/influence-of-the-selective-antagonist-of-the-nr2b-subunit-of-the-nmda-receptor-traxoprodil-on-the-antidepressant-like-activity-of-desipramine-paroxetine-milnacipran-and-bupropion-in-mice
#15
Weronika Stasiuk, Aleksandra Szopa, Anna Serefko, Elżbieta Wyska, Katarzyna Świąder, Jarosław Dudka, Piotr Wlaź, Ewa Poleszak
Pre-clinical and clinical studies indicated that a blockade of the NMDA receptor complex creates new opportunities for the treatment of affective disorders, including depression. The aim of the present study was to assess the influence of traxoprodil (10 mg/kg) on the activity of desipramine (10 mg/kg), paroxetine (0.5 mg/kg), milnacipran (1.25 mg/kg), and bupropion (10 mg/kg), each at sub-therapeutic doses. Moreover, brain levels of traxoprodil and tested agents were determined using HPLC. The obtained results were used to ascertain the nature of occurring interaction between traxoprodil and studied antidepressants...
March 2017: Journal of Neural Transmission
https://www.readbyqxmd.com/read/27889704/pharmacogenetic-studies-a-tool-to-improve-antidepressant-therapy
#16
Marta Ramos, Cecilia Berrogain, Julia Concha, Laura Lomba, Cristina Belén García, Mª Pilar Ribate
The World Health Organization (WHO) predicts that major depressive disorder (MDD) will be the second leading cause of death and disability by 2020. Nowadays, approximately 60-70% of patients with this disorder have shown the lack of effectiveness and tolerability of the therapy with antidepressants. The US Food and Drug Administration (FDA) and the European Medicine Agency (EMA) are including pharmacogenetic information in the labeling of several antidepressants. The presence of this information represents the relevance of genetic polymorphisms in drug response...
December 1, 2016: Drug Metabolism and Personalized Therapy
https://www.readbyqxmd.com/read/27888525/breaking-sad-unleashing-the-breakthrough-potential-of-ketamine-s-rapid-antidepressant-effects
#17
David Feifel
Preclinical Research The surprising results of a small clinical trial on the effects of low dose ketamine, a 65-year old anesthetic drug that is also used off-label for chronic pain and recreationally as a club drug, in eight depressed subjects unleashed the most significant advance in antidepressant drug development in decades. That study and subsequent ones have demonstrated that low dose, infused ketamine is able to induce a remission of depression in patients who have failed conventional medications, within 24 h...
December 2016: Drug Development Research
https://www.readbyqxmd.com/read/27854435/-rhodiola-rosea-and-its-neuropsychotropic-effects
#18
Jan Juřica, Tereza Koupá
The paper reviews the neuropsychotropic effects of Rhodiola rosea, a succulent perennial plant which is native to dry, high-altitude regions of the northern hemisphere. The most valued part of the plant is its rhizome, which has a rose-like fragrance. In the available literature, there is a large number of mentions of its healing properties; nonetheless, only few of them are based on reliable scientific evidence. Of the neuropsychotropic effects, there are mentions of anxiolytic, antidepressant, neuroprotective and pro- cognitive properties and nonspecific "adaptogenic" effects...
2016: Ceská a Slovenská Farmacie
https://www.readbyqxmd.com/read/27846049/agomelatine-for-the-treatment-of-major-depressive-episodes-in-schizophrenia-spectrum-disorders-an-open-prospective-proof-of-concept-study
#19
Susanne Englisch, Hanna Sophie Jung, Antje Lewien, Anna Becker, Ulrike Nowak, Hanna Braun, Jascha Thiem, Sarah Eisenacher, Andreas Meyer-Lindenberg, Mathias Zink
BACKGROUND: Depressive episodes in schizophrenia constitute a major clinical problem, and treatment success is often limited by treatment-emergent side effects. Agomelatine, an agonist at melatonergic MT1/MT2 receptors and 5-HT2C receptor antagonist, is a new antidepressant with a novel mode of action which constitutes a potential therapeutic option for depression in schizophrenia. METHODS: Twenty-seven patients with lifetime diagnoses within the schizophrenia spectrum and comorbid depression were treated with agomelatine in addition to stable doses of antipsychotic agents...
October 29, 2016: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27836670/in-vitro-to-in-vivo-extrapolation-of-the-complex-drug-drug-interaction-of-bupropion-and-its-metabolites-with-cyp2d6-simultaneous-reversible-inhibition-and-cyp2d6-downregulation
#20
Jennifer E Sager, Sasmita Tripathy, Lauren S L Price, Abhinav Nath, Justine Chang, Alyssa Stephenson-Famy, Nina Isoherranen
Bupropion is a widely used antidepressant and smoking cessation aid and a strong inhibitor of CYP2D6 in vivo. Bupropion is administered as a racemic mixture of R- and S-bupropion and has stereoselective pharmacokinetics. Four primary metabolites of bupropion, threo- and erythro-hydrobupropion and R,R- and S,S-OH-bupropion, circulate at higher concentrations than the parent drug and are believed to contribute to the efficacy and side effects of bupropion as well as to the CYP2D6 inhibition. However, bupropion and its metabolites are only weak inhibitors of CYP2D6 in vitro, and the magnitude of the in vivo drug-drug interactions (DDI) caused by bupropion cannot be explained by the in vitro data even when CYP2D6 inhibition by the metabolites is accounted for...
January 1, 2017: Biochemical Pharmacology
keyword
keyword
81989
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"